Take note that all the analysts who all got it wrong raised their target, so CYA is in full swing.
As posted Insmed dropped the filing in the US on compelling data since the data wasnt compelling.
Cannacord thinks the NTM results are now 1st quarter 2014, which makes perfect business sense for those analysts with tax loss selling - )
How Cannacord could say invitro work or these results would support anything is unbelievable...
Approval mentioned for Europe...I agree, what I disagree is that the drug gets the EU agencys seal of good coverage.
but this one
"While there are optical imbalances in Arikace’s severe adverse events, INSM indicated
there is no kidney or ototox signal, our main concern. We look forward to
reviewing more details at medical meetings/in publication later this year."
Ill let investors of bio and the fact the prelininary adverse data was not good decide.
"As posted Insmed dropped the filing in the US on compelling data since the data wasnt compelling."
Stick to telling us about your make-believe life as a trader Terry. At least with that there's usually no indisputable proof you're lying. But after the recent fiasco I suggest you take a bit more trouble to be consistent with your lies.